Scarica l'app Stockscreener
2.09
1.95%
0.04
Dopo l'orario di chiusura:
2.13
0.04
+1.91%
Precedente Chiudi:
$2.05
Aprire:
$2.06
Volume 24 ore:
29,062
Relative Volume:
0.30
Capitalizzazione di mercato:
$9.49M
Reddito:
-
Utile/perdita netta:
$-31.88M
Rapporto P/E:
-2.7867
EPS:
-0.75
Flusso di cassa netto:
$-25.20M
1 W Prestazione:
+4.50%
1M Prestazione:
-7.52%
6M Prestazione:
-69.43%
1 anno Prestazione:
-77.37%
Intervallo 1D:
$2.05
$2.1313
Intervallo di 1 settimana:
$1.99
$2.1799
Portata 52W:
$1.91
$16.70
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Confronta INAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.09 | 9.31M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-18 | Iniziato | Laidlaw | Buy |
| 2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Layoff Tracker: Arvinas Downsizes by 15% After Punting Pfizer-Partnered Asset - BioSpace
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes - biospace.com
KALA BIO Soars 10.65% on Bullish Analyst Coverage - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Does Gossamer Bio Inc. align with a passive investing strategyJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 - GlobeNewswire
Rare Eye Disease Biotech KALA BIO to Present Latest Developments at H.C. Wainwright Conference - Stock Titan
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director - GlobeNewswire
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - The Globe and Mail
Gamma Delta T Cell Therapy Pioneer Adicet Bio to Showcase Latest Developments at Global Investment Conference - Stock Titan
First-in-Class TSLP Antibody Results: Upstream Bio's Verekitug Phase 2 Trial in Nasal Polyps Coming - Stock Titan
Signal strength of KALA BIO Inc. stock in tech scannersJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Is Palisade Bio Inc. trending in predictive chart modelsMarket Sentiment Review & Weekly Hot Stock Watchlists - Newser
Historical volatility pattern of GRI Bio Inc. visualizedDay Trade & Fast Momentum Entry Tips - Newser
Will a bounce in Instil Bio Inc. offer an exit2025 Biggest Moves & AI Powered Buy and Sell Recommendations - Newser
TELA Bio Inc. stock momentum explainedJuly 2025 Patterns & Stock Market Timing Techniques - Newser
Understanding Instil Bio Inc.’s price movementMarket Growth Review & Safe Swing Trade Setups - Newser
Regression analysis insights on GRI Bio Inc. performanceJuly 2025 Review & Fast Gaining Stock Reports - Newser
How to forecast Passage Bio Inc. trends using time series2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
84,000 Shares at $0.72: Adicet Bio's Latest Inducement Grants Under Nasdaq Rule 5635(c)(4) - Stock Titan
Smart tools for monitoring KALA BIO Inc.’s price actionAnalyst Upgrade & Proven Capital Preservation Tips - Newser
PAH Drug Developer Gossamer Bio Set for Key Presentations at Cantor, Wells Fargo, HC Wainwright Events - Stock Titan
Is Nuvation Bio Inc. stock poised for growthJuly 2025 Breakouts & AI Optimized Trade Strategies - Newser
Trend analysis for Adicet Bio Inc. this weekBull Run & Stock Timing and Entry Methods - Newser
What candlestick patterns are forming on bluebird bio Inc.Stop Loss & Free AI Powered Buy and Sell Recommendations - Newser
What’s next for INmune Bio Inc. stock priceWeekly Trade Review & Entry Point Confirmation Signals - Newser
Genetic Medicines Pioneer Passage Bio to Showcase Neurodegenerative Disease Pipeline at Global Conference - Stock Titan
Visualizing Third Harmonic Bio Inc. stock with heatmaps2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
Global Oncology Company Nuvation Bio Announces Triple Conference Schedule for September 2025 - Stock Titan
Is now a turning point for Adicet Bio Inc.Weekly Risk Summary & Daily Oversold Stock Bounce Ideas - Newser
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):